The pharmaceutical industry is the process of finding, developing, and producing pharmaceutical products. It’s pervasive and involves government agencies, research, chemicals, and regulation.
Here are three stocks that derive up to 50% of their revenue from the United States of America.
Aurobindo Pharma Ltd.
Aurobindo Pharma is engaged in the production and distribution of generic medications, active pharmaceutical ingredients, and associated services.
With a market capitalization of Rs 58,488.39 crores. Aurobindo Pharma Ltd, On Monday the company’s shares closed at Rs 998.20 a share, a decrease of 0.92 percent from the previous close price.
Aurobindo Pharma Ltd.’s revenue from the USA is Rs 11,654 crores, and the US market contributes 47 percent to the total revenue mix. Similarly, the Company generated Rs 6,426 crores in revenue from the European region.
Aurobindo Pharma Ltd.’s revenue increased by 25.7 percent from Rs 5,739.37 Crore in Q2FY23 to 7,219.42 Crore in Q2FY24. During the same period, net profits increased by 182 percent from Rs 411.6 Cr to Rs 751.04 Cr.
Cipla Ltd
Cipla mainly creates medications to treat a wide range of illnesses, including depression, diabetes, rheumatoid arthritis, and cardiovascular disease.
With a market capitalization of Rs 1,00,685.59 crores. Cipla Ltd, On, Monday the company’s shares closed at Rs 1,247.15 a share, a decrease of 0.18 percent from the previous close price.
The US business’s share of Cipla’s worldwide revenue increased from 20% in FY 2021–2022 to 26% in FY 2022–2023. The company generated a total revenue of 3,073.15 Crore.
Cipla’s revenue increased by 25.7 percent from Rs 5,739.37 Crore in Q2FY23 to 7,219.42 Crore in Q2FY24. During the same period, net profits increased by 182 percent from Rs 411.6 Cr to Rs 751.04 Cr.
Dr. Reddey Laboraties Ltd
One of the top pharmaceutical companies in India is Dr. Reddy’s Laboratories Ltd. It provides a range of goods and services, such as APIs (active pharmaceutical ingredients), CPS (custom pharmaceutical services), generics, biosimilars, and unique formulations.
With a market capitalization of Rs 93,366.84 crores. Dr. Reddey Laboraties Ltd, On Monday the company’s shares closed at Rs 5,597.90 a share, a decrease of 0.17 percent from the previous close price.
Dr. Reddey Laboraties Ltd’s revenue from the USA is Rs 10,170.04 crores, and the US market contributes 41 percent to the total revenue mix. Similarly, the Company generated Rs 10,100 crores in revenue from the European region.
Dr. Reddey Laboraties Ltd’s revenue increased by 9.01 percent from Rs 6,331.8 Crore in Q2FY23 to 6,902.6 Crore in Q2FY24. During the same period, net profits increased by 34 percent from Rs 1,100.2 Crore to Rs 1,478 Crore.
Written by:- Abhishek Singh